Is the AI bubble about to burst? The growing consensus among analysts and watchdogs is that the market faces impending doom. 

This is the “biggest and most dangerous bubble the world has ever seen,” one market researcher proclaimed this month. “We are absolutely in an AI bubble. It’s going to burst,” the co-founder of an activist investor firm said this week. Even AI chatbots own up to the market’s troubles when asked, with one pointing to the growing “gap between promised breakthroughs and actual deliverables,” Forbes reported. 

Not everyone agrees the market is in grave danger. And while the rapid rise of AI startups has certainly infiltrated pharma, the industry could be more insulated from wider market turbulence. Today, we’re looking at the three most valuable AI companies in pharma, how they’re impacting drug development and why the technology’s presence in the industry could be more sustainable than in the consumer sector. 

What’s your take? In our survey below, tell us if you think there’s an AI bubble in pharma. 

Thanks for reading.